Generic Viracept Availability

Viracept is a brand name of nelfinavir, approved by the FDA in the following formulation(s):

VIRACEPT (nelfinavir mesylate - tablet;oral)

  • Manufacturer: AGOURON
    Approval date: March 14, 1997
    Strength(s): EQ 250MG BASE [RLD]
  • Manufacturer: AGOURON
    Approval date: April 30, 2003
    Strength(s): EQ 625MG BASE [RLD]

Has a generic version of Viracept been approved?

No. There is currently no therapeutically equivalent version of Viracept available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viracept. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • HIV protease inhibitors
    Patent 5,484,926
    Issued: January 16, 1996
    Inventor(s): Dressman; Bruce A. & Fritz; James E. & Hammond; Marlys & Hornback; William J. & Kaldor; Stephen W. & Kalish; Vincent J. & Munroe; John E. & Reich; Siegfried H. & Tatlock; John H. & Shepherd; Timothy A. & Rodriguez; Michael J.
    Assignee(s): Agouron Pharmaceuticals, Inc.
    HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Patent expiration dates:
    • October 7, 2013
    • April 7, 2014
      ✓ 
      Pediatric exclusivity
  • HIV protease inhibitors
    Patent 5,952,343
    Issued: September 14, 1999
    Inventor(s): Dressman; Bruce A. & Fritz; James E. & Hornback; William J. & Kaldor; Stephen W. & Kalish; Vincent J. & Munroe; John E. & Reich; Siegfried Heinz & Tatlock; John H. & Shepherd; Timothy A. & Rodriguez; Michael J.
    Assignee(s): Agouron Pharmaceuticals, Inc.
    HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Patent expiration dates:
    • October 7, 2013
      ✓ 
      Patent use: TREATMENT OF HIV INFECTION
    • April 7, 2014
      ✓ 
      Pediatric exclusivity
  • Pharmaceutical compositions containing HIV protease inhibitors and methods of their use
    Patent 6,162,812
    Issued: December 19, 2000
    Inventor(s): Dressman; Bruce A. & Fritz; James E. & Hammond; Marlys & Hornback; William J. & Kaldor; Stephen W. & Kalish; Vincent J. & Munroe; John E. & Reich; Siegfried Heinz & Tatlock; John H. & Shepherd; Timothy A. & Rodriguez; Michael J.
    Assignee(s): Agouron Pharmaceuticals, Inc.
    HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Patent expiration dates:
    • October 7, 2013
      ✓ 
      Patent use: TREATMENT OF HIV
    • April 7, 2014
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web5)